EGFR and lung adenocarcinoma: This was confirmed by numerous reports from frequently assessed populations, showing a huge variability of EGFR mutation frequencies in patients with lung adenocarcinoma, ranging between 6 and 41% in Europe, 3 and 42% in North America, and 20 and 76% in Asia-Pacific [33].